A critical narrative review synthesizes evidence from over eighty studies demonstrating that artificial intelligence applied ...
A clinical case report documents an asymptomatic 73-year-old prostate cancer patient whose biochemical recurrence led to the ...
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...
Men's Fitness on MSN
Your prostate at 40, 50, 60 and 70: what's normal, what's not and when to be concerned
What happens to your prostate as you get older? One expert explains what's normal at 40, 50, 60 and 70, common symptoms to ...
Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to ...
Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec ...
The 2026 ESMO annual meeting featured a prostate cancer proffered paper session and a discussant presentation by Dr. Nicholas van As discussing two abstracts “Perioperative apalutamide + ADT with ...
Montell Jordan recalled Q Parker's early morning hospital visits during cancer treatment and the support his wife helped ...
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he ...
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
The studies explore how gene expression can provide insights beyond individual genetic alterations to inform thyroid nodule diagnosis and assessment of cancer aggressiveness. Oral presentations from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results